RPRX Stock Recent News

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma offers a unique exposure in the pharmaceutical sector thanks to a diversified portfolio and lower operational risk vs. competitors. The Vertex franchise is a significant contributor to Royalty Pharma's earnings and this ongoing risk appears manageable, given the company's solid execution and new royalties acquisition. Valuation discount vs. peers and other royalties companies. Ongoing buyback, in line with dividend yield, coupled with cash at the bank. With these fundamentals, the valuation looks very attractive.

Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnership with Ferring Pharmaceuticals, investing $300 million upfront for royalties on bladder cancer drug. Debate over VX-121 royalties is overstated, with limited impact on Royalty Pharma's valuation.

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Royalty Pharma (RPRX) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.79 per share a year ago.

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Shares of biopharmaceutical royalty concern Royalty Pharma plc have fallen 45% from their all-time high as inflation and a potential revenue decline from its number one asset weigh. Vertex Pharmaceuticals Incorporated, the maker of multi-blockbuster cystic fibrosis med Trikafta, is advancing a candidate through Phase 3 trials that could lower its royalty burden to the company by two-thirds. With a $1 billion share repurchase program just announced, the recent buying by the Founder and CEO merited a deeper dive.

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to a milestone payment, this year's cash receipts will come in close to $3B. The annualized free cash flow result for the next few years will likely average $2B.

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m. PT.